Immix Biopharma (IMMX) Gains from Sales and Divestitures (2023 - 2025)
Quarterly results put Gains from Sales and Divestitures at $41023.0 for Q1 2025, down 87.96% from a year ago — trailing twelve months through Mar 2025 was $41023.0 (down 87.96% YoY), and the annual figure for FY2024 was $111444.0, down 71.07%.
Immix Biopharma has reported Gains from Sales and Divestitures over the past 3 years, most recently at $41023.0 for Q1 2025.
- Gains from Sales and Divestitures reached $41023.0 in Q1 2025 per IMMX's latest filing, down from $111444.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $429504.0 in Q3 2023 and bottomed at $21876.0 in Q1 2023.
- Median Gains from Sales and Divestitures over the past 3 years was $252287.0 (2024), compared with a mean of $230023.6.
- The largest annual shift saw Gains from Sales and Divestitures skyrocketed 1457.91% in 2024 before it tumbled 87.96% in 2025.
- Over 3 years, Gains from Sales and Divestitures stood at $385156.0 in 2023, then plummeted by 71.07% to $111444.0 in 2024, then tumbled by 63.19% to $41023.0 in 2025.
- Business Quant data shows Gains from Sales and Divestitures for IMMX at $41023.0 in Q1 2025, $111444.0 in Q4 2024, and $181864.0 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 41,023.00 |
| Mar 31, 2025 | 41,023.00 |
| Dec 31, 2024 | 111,444.00 |
| Dec 31, 2024 | 111,444.00 |
| Sep 30, 2024 | 181,864.00 |
| Sep 30, 2024 | 181,864.00 |
| Jun 30, 2024 | 252,287.00 |
| Jun 30, 2024 | 252,287.00 |
| Mar 31, 2024 | 340,808.00 |
| Mar 31, 2024 | 340,808.00 |
| Dec 31, 2023 | 385,156.00 |
| Dec 31, 2023 | 385,156.00 |
| Sep 30, 2023 | 429,504.00 |
| Sep 30, 2023 | 429,504.00 |
| Jun 30, 2023 | 306,250.00 |
| Jun 30, 2023 | 306,250.00 |
| Mar 31, 2023 | 21,876.00 |
| Mar 31, 2023 | 21,876.00 |